Literature DB >> 11133372

Generation of alloantigen-stimulated anti-human immunodeficiency virus activity is associated with HLA-A*02 expression.

E Grene1, L A Pinto, S S Cohen, M T Trivett, T B Simonis, D J Liewehr, S M Steinberg, G M Shearer.   

Abstract

Stimulation of peripheral blood mononuclear cells (PBMC) with allogeneic PBMC (ALLO) can result in activity that inhibits the replication of human immunodeficiency virus (HIV). The present study demonstrates that strong anti-HIV activity is dependent on expression of HLA-A*02 by the responding PBMC. Anti-HIV activity was equally effective against 2 primary isolates that use different coreceptors. Neither ALLO-stimulated cell proliferation nor cytokine and beta-chemokine production was associated with the expression of HLA-A*02. ALLO-stimulated production of strong anti-HIV activity required intact PBMC and was not inhibited by monoclonal antibodies directed against nonpolymorphic regions of human leukocyte antigens (HLAs). Anti-HIV activity was generated by ALLO-stimulated CD4(+) cells, CD8(+) T lymphocytes, and monocytes from HLA-A*02-positive patients. These findings provide the first evidence that the production of an HIV inhibitory factor or factors is associated with certain HLA genes and raise new possibilities concerning the role of the major histocompatibility complex in controlling viral infections via alloantigen stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11133372     DOI: 10.1086/318085

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors:  G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.

Authors:  Theresa Li-Yun Chang; Arevik Mosoian; Richard Pine; Mary E Klotman; John P Moore
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Prior mucosal exposure to heterologous cells alters the pathogenesis of cell-associated mucosal feline immunodeficiency virus challenge.

Authors:  Surender B Kumar; Sarah Leavell; Kyle Porter; Barnabe D Assogba; Mary J Burkhard
Journal:  Retrovirology       Date:  2010-05-28       Impact factor: 4.602

4.  Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers.

Authors:  W Jennes; D Evertse; M-Y Borget; B Vuylsteke; C Maurice; J N Nkengasong; L Kestens
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

5.  Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission.

Authors:  Carey Farquhar; Sarah Rowland-Jones; Dorothy Mbori-Ngacha; Mary Redman; Barbara Lohman; Jennifer Slyker; Phelgona Otieno; Elizabeth Obimbo; Timothy Rostron; James Ochieng; Julius Oyugi; Rose Bosire; Grace John-Stewart
Journal:  AIDS Res Hum Retroviruses       Date:  2004-07       Impact factor: 2.205

6.  The evolutionary significance of certain amino acid substitutions and their consequences for HIV-1 immunogenicity toward HLA's A*0201 and B*27.

Authors:  Luke Hecht; Anton Dormer
Journal:  Bioinformation       Date:  2013-03-19

7.  HLA A*32 is associated to HIV acquisition while B*44 and B*53 are associated with protection against HIV acquisition in perinatally exposed infants.

Authors:  Linda Mouafo Mekue; Céline Nguefeu Nkenfou; Elvis Ndukong; Leaticia Yatchou; Beatrice Dambaya; Marie-Nicole Ngoufack; Joel Kadji Kameni; Jules-Roger Kuiaté; Alexis Ndjolo
Journal:  BMC Pediatr       Date:  2019-07-23       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.